Skip to main content
OpenTrials

Clinical trial condition

Myeloproliferative Disorders

Explore clinical trials studying Myeloproliferative Disorders. Study availability and eligibility vary by location and protocol.

1,108 public trials 143 recruiting studies
Refine in advanced search Browse all conditions

Myeloproliferative Disorders trial results

Completed

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

NCT01856283

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +11 more
Locations
  • A.O. Ospedale S. Antonio Gallarate, Milano, Italy
  • Ospedale Desio- "Ospedale Civile" di Vimercate, Desio, Carate Brianza, Giussano, Seregno. Vimercate, Milano, Italy
  • A.O di Circolo di Busto Arsizio Busto Arsizio, Varese, Italy
  • Ospedali Riuniti Bergamo Bergamo, Italy
View all 17 locations
View Trial Details
Completed

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

NCT01077544

Conditions
Acute Lymphoblastic Leukemia, Bone Marrow Diseases, Chronic Disease, +18 more
Locations
  • Novartis Investigative Site Bordeaux, Aquitaine, France
  • Novartis Investigative Site Lille, France
  • Novartis Investigative Site Paris, France
  • Novartis Investigative Site Poitiers, France
View Trial Details
Completed

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

NCT01456676

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +11 more
Locations
  • Novartis Investigative Site Toronto, Ontario, Canada
  • Novartis Investigative Site Marseille, France
  • Novartis Investigative Site Frankfurt, Germany
  • Novartis Investigative Site Ulm, Germany
View Trial Details
Completed

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

NCT01223898

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myeloid Leukemia, +11 more
Locations
  • Novartis Investigative Site Frankfurt/M, Germany
  • Novartis Investigative Site Jena, Germany
  • Novartis Investigative Site Mannheim, Germany
  • Novartis Investigative Site Ulm, Germany
View Trial Details

Related conditions